Brooks Laboratories Reports Strongest Sales and Profit Metrics Since Last Year

Brooks Laboratories, a microcap company in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending March 2025. The results indicate a notable performance, with net sales reaching Rs 23.32 crore, marking the highest figure in the last five quarters. This represents a growth of 21.2% compared to the average net sales of the previous four quarters, which stood at Rs 19.24 crore. Additionally, the company recorded its highest profit before tax (PBT) in the last five quarters at Rs -1.90 crore, alongside a profit after tax (PAT) of Rs -1.46 crore, also the highest in the same timeframe. The earnings per share (EPS) improved to Rs -0.56, reflecting a trend towards increased profitability and enhanced earnings for shareholders. Despite these positive indicators, Brooks Laboratories has experienced an adjustment in its evaluation, with its score falling to 6 from 7 over the past three months. This revision highlights the dynamic nature of the company's financial assessment. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.